Study title:
A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
Date receipt dossier:
25 oct 2016
EudraCT number:
2016-003312-12
Company / Sponsor:
Celyad
Phase:
I
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
cancer
Therapeutic approach:
Immunotherapy
Genetic modification:
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest:
Moloney Murine Leukemia Virus
Administered biological material:
Autologous T-cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration:
Intravenous
Locations in Belgium:
UZ Gent, Grand Hôpital de Charleroi
Nr of subjects:
24 participants
Foreseen duration:
4 years
Type of procedure:
Contained use only
Current status:
Authorized